The USPTO announced a public challenge in support of the National Cancer Moonshot Initiative. The USPTO is asking the public to investigate and leverage the intellectual property data within the USPTO and combine it with other economic and funding data (e.g., SEC filings, FDA reporting, National Science Foundation grants and other funding sources) to “reveal new insights into investments around cancer therapy research and treatments.” Issues that may be explored include the peaks and valleys in the landscape of cancer treatment technologies, insights revealed by correlating R&D spending/funding to breakthrough technologies, and whether trace studies of commercially successful treatments from patent to product would informative.
A workshop will be held on Thursday August 25th, 2016 to assist participants with the challenge. The challenge concludes on September 12th and winners will be announced on September 26th, 2016.
The USPTO hopes that the information gleaned from the challenge will support cancer research and the development of new commercialized therapies. As noted by the office “[t]his will empower the federal government—as well as the medical, research, and data communities—to make more precise funding and policy decisions based on the commercialization lifecycle of the most promising treatments, and maximize U.S. competitiveness in cancer investments.”
A workshop will be held on Thursday August 25th, 2016 to assist participants with the challenge. The challenge concludes on September 12th and winners will be announced on September 26th, 2016.
The USPTO hopes that the information gleaned from the challenge will support cancer research and the development of new commercialized therapies. As noted by the office “[t]his will empower the federal government—as well as the medical, research, and data communities—to make more precise funding and policy decisions based on the commercialization lifecycle of the most promising treatments, and maximize U.S. competitiveness in cancer investments.”
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Author(s)
Related Insights
19 February 2025
Manufacturing Industry Advisor
Foley Automotive Update
Foley is here to help you through all aspects of rethinking your long-term business strategies, investments, partnerships, and technology. Contact the authors, your Foley relationship partner, or our Automotive Team to discuss and learn more.
19 February 2025
Manufacturing Industry Advisor
What Every Multinational Company Should Know About … The New Steel and Aluminum Tariffs
On February 10, 2025, President Trump signed proclamations titled Adjusting Imports of Steel Into the United States and Adjusting Imports of Aluminum into the United States. The proclamations cover both steel and aluminum tariffs, which will be raised to a flat 25%.
18 February 2025
Labor & Employment Law Perspectives
Noncompete Bans – Next Up: Ohio
This month, Ohio joined the list of states with pending legislation to ban noncompetes. With the FTC noncompete ban blocked on a nationwide basis last year, Ohio lawmakers introduced a bill on February 5, 2025, that would ban noncompete contracts as a condition of employment in the state.